Biotech Daily Market Report October 13, 2006
October 13th 2006 07:54
ASX, BIOTECHS UP:
METABOLIC UP 10.5%, CYGENICS DOWN 9%
THE MARKET
The Australian stock market climbed 0.60 percent on Friday October 13, 2006, with the All Ordinaries up 30.0 points to 5,253.9 points. Nineteen of the Biotech Daily Top 40 stocks were up, 13 stocks fell, six traded unchanged and two were untraded. Fifteen of the Top 20 rose and three fell, while four of the Second 20 rose and 10 fell.
Metabolic was best continuing its week long climb (see separate story) closing up 6.5 cents or 10.48 percent at 68.5 cents with 1.9 million shares traded. Psivida was next best, up 2.5 cents or 8.62 percent to 31.5 cents with 1.5 million shares traded, followed by Biosignal up 8.57 percent to 19 cents, Bionomics up 6.45 percent to 16.5 cents, Alchemia up 5.38 percent and Phylogica up 4.17 percent.
Optiscan and Starpharma were up more than three percent; Living Cell, Peplin, Pharmaxis, Prana and Sirtex were up more than two percent; with Acrux, Cochlear, CSl and Resmed up by more than one percent.
Cygenics led the falls, down three cents or 8.57 percent to 32 cents on modest volumes. Agenix, Cogstate and Proteome fell more than six percent; Neuren lost 5.88 percent to 40 cents; Polartechnics fell 4.55 percent; Phosphagenics, Portland and Tissue Therapies were down more than two percent; with Chemgenex, Clinical Cell, Genetic Technologies and Prima down more than one percent.
TODAY'S NEWS
* PATIENT RECOVERS: VENTRACOR PUMP REMOVED
* METABOLIC TRADES HEAVILY ABOVE 60¢
* STARPHARMA AGM CONSIDERS DIRECTORS POOL RISE TO $450k
* PEPLIN AGM OVERCOMES SHAREHOLDER DISSENT
* PSIRON OPEN FOR US TRADING
* RESONANCE APPOINTS PAUL JOBBINS CFO
To view these articles readers need to subscribe to Biotech Daily.
See details at www.biotechdaily.com.au
| 35 |
| Vote |
Add To: 
subscribe to this blog